Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858585 · ClinicalTrials.gov registry record
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 149
- Enrollment target
NCT00858585: Completed study, sponsored by University of Michigan Rogel Cancer Center.
NCT00858585 is a clinical trial that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 149 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00858585 has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 149 participants
- Enrollment target
Study Summary
This study will examine genes in three different tissues and look for similarities and differences between normal cells and cancer cells. The tissues to be studies come from blood, lymph node and cancer.
Primary Outcome
Determine single nucleotide polymorphism concordances between the three DNA specimen sources
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2009-03 |
| Est. Completion | 2016-09 |
What the finished NCT00858585 record still lists
NCT00858585 is an observational study that tracks outcomes without assigning an intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00858585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00858585 about?
NCT00858585 is a clinical study titled "Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study". This study will examine genes in three different tissues and look for similarities and differences between normal cells and cancer cells. The tissues to be studies come from blood, lymph node and cancer.
What is the current status of trial NCT00858585?
This trial is currently completed. The enrollment target is 149 participants. The study started on 2009-03. Estimated completion is 2016-09.
Who is sponsoring clinical trial NCT00858585?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia